{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:33:53Z","timestamp":1788327233551,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The progression of cancer from localized to metastatic disease is the primary cause of morbidity and mortality. The interplay between the tumor and its microenvironment is the key driver in this process of tumor progression. In order for tumors to progress and metastasize they must reprogram the cells that make up the microenvironment to promote tumor growth and suppress endogenous defense systems, such as the immune and inflammatory response. We have previously demonstrated that stimulation of Tsp-1 in the tumor microenvironment (TME) potently inhibits tumor growth and progression. Here, we identify a novel tumor-mediated mechanism that represses the expression of Tsp-1 in the TME via secretion of the serine protease PRSS2. We demonstrate that PRSS2 represses Tsp-1, not via its enzymatic activity, but by binding to low-density lipoprotein receptor-related protein 1 (LRP1). These findings describe a hitherto undescribed activity for PRSS2 through binding to LRP1 and represent a potential therapeutic strategy to treat cancer by blocking the PRSS2-mediated repression of Tsp-1. Based on the ability of PRSS2 to reprogram the tumor microenvironment, this discovery could lead to the development of therapeutic agents that are indication agnostic.<\/jats:p>","DOI":"10.1038\/s41467-022-35649-9","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T07:02:46Z","timestamp":1672124566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression"],"prefix":"10.1038","volume":"13","author":[{"given":"Lufei","family":"Sui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debolina","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9935-388X","authenticated-orcid":false,"given":"Tyler P.","family":"El Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Askeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"B\u00f8rretzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Johan","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f8ril","family":"Knutsvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarle","family":"Arnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sura","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein","family":"Haukaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7427-4651","authenticated-orcid":false,"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane R.","family":"Bielenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturas","family":"Ziemys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4764-7413","authenticated-orcid":false,"given":"Vivek","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-2377","authenticated-orcid":false,"given":"Rolf A.","family":"Brekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars A.","family":"Akslen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-5638","authenticated-orcid":false,"given":"Randolph S.","family":"Watnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"35649_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1126\/science.1150224","volume":"319","author":"D Gao","year":"2008","unstructured":"Gao, D. et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319, 195\u2013198 (2008).","journal-title":"Science"},{"key":"35649_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","volume":"127","author":"GP Gupta","year":"2006","unstructured":"Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679\u2013695 (2006).","journal-title":"Cell"},{"key":"35649_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"JA Joyce","year":"2009","unstructured":"Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239\u2013252 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"35649_CR4","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/2159-8290.CD-12-0476","volume":"3","author":"R Catena","year":"2013","unstructured":"Catena, R. et al. Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578\u2013589 (2013).","journal-title":"Cancer Discov."},{"key":"35649_CR5","doi-asserted-by":"publisher","first-page":"12115","DOI":"10.1073\/pnas.0903120106","volume":"106","author":"SY Kang","year":"2009","unstructured":"Kang, S. Y. et al. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc. Natl Acad. Sci. USA 106, 12115\u201312120 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35649_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820\u2013827 (2005).","journal-title":"Nature"},{"key":"35649_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","volume":"88","author":"MS O\u2019Reilly","year":"1997","unstructured":"O\u2019Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277\u2013285 (1997).","journal-title":"Cell"},{"key":"35649_CR8","first-page":"98","volume":"8","author":"P S","year":"1889","unstructured":"S, P. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98\u2013101 (1889).","journal-title":"Cancer Metastasis Rev."},{"key":"35649_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306\u20131309 (1989).","journal-title":"Science"},{"key":"35649_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983\u2013985 (1983).","journal-title":"Science"},{"key":"35649_CR11","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"D Gabrilovich","year":"1998","unstructured":"Gabrilovich, D. et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150\u20134166 (1998).","journal-title":"Blood"},{"key":"35649_CR12","doi-asserted-by":"publisher","first-page":"6808","DOI":"10.1158\/1078-0432.CCR-06-1558","volume":"12","author":"B Li","year":"2006","unstructured":"Li, B. et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res. 12, 6808\u20136816 (2006).","journal-title":"Clin. Cancer Res."},{"key":"35649_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nm.3541","volume":"20","author":"GT Motz","year":"2014","unstructured":"Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607\u2013615 (2014).","journal-title":"Nat. Med."},{"key":"35649_CR14","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","volume":"160","author":"T Oyama","year":"1998","unstructured":"Oyama, T. et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160, 1224\u20131232 (1998).","journal-title":"J. Immunol."},{"key":"35649_CR15","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.1158\/0008-5472.CAN-08-0643","volume":"68","author":"G Martin-Manso","year":"2008","unstructured":"Martin-Manso, G. et al. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 68, 7090\u20137099 (2008).","journal-title":"Cancer Res."},{"key":"35649_CR16","doi-asserted-by":"publisher","first-page":"329ra334","DOI":"10.1126\/scitranslmed.aad5653","volume":"8","author":"S Wang","year":"2016","unstructured":"Wang, S. et al. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci. Transl. Med. 8, 329ra334 (2016).","journal-title":"Sci. Transl. Med."},{"key":"35649_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(96)90078-1","volume":"347","author":"J Hedstrom","year":"1996","unstructured":"Hedstrom, J. et al. Urinary trypsinogen-2 test strip for acute pancreatitis. Lancet 347, 729\u2013730 (1996).","journal-title":"Lancet"},{"key":"35649_CR18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/clinchem\/42.5.685","volume":"42","author":"J Hedstrom","year":"1996","unstructured":"Hedstrom, J. et al. Urine trypsinogen-2 as marker of acute pancreatitis. Clin. Chem. 42, 685\u2013690 (1996).","journal-title":"Clin. Chem."},{"key":"35649_CR19","first-page":"712","volume":"115","author":"O Itkonen","year":"1990","unstructured":"Itkonen, O. et al. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J. Lab Clin. Med. 115, 712\u2013718 (1990).","journal-title":"J. Lab Clin. Med."},{"key":"35649_CR20","doi-asserted-by":"publisher","first-page":"TPS3158","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3158","volume":"37","author":"M Cieslewicz","year":"2019","unstructured":"Cieslewicz, M. et al. A phase I open label study evaluating VT1021 in patients with advanced solid tumors. J. Clin. Oncol. 37, TPS3158\u2013TPS3158 (2019).","journal-title":"J. Clin. Oncol."},{"key":"35649_CR21","first-page":"A228","volume":"8","author":"D Mahalingam","year":"2020","unstructured":"Mahalingam, D. et al. 374 A first-in-human phase 1\/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors. J. Immunother. Cancer 8, A228\u2013A228 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"35649_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/pros.20236","volume":"64","author":"A Bjartell","year":"2005","unstructured":"Bjartell, A. et al. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 64, 29\u201339 (2005).","journal-title":"Prostate"},{"key":"35649_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/0284186X.2020.1733655","volume":"59","author":"A Kasurinen","year":"2020","unstructured":"Kasurinen, A. et al. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer. Acta Oncol. 59, 681\u2013688 (2020).","journal-title":"Acta Oncol."},{"key":"35649_CR24","doi-asserted-by":"publisher","unstructured":"Narasimhan, A. et al. Identification of potential serum protein biomarkers and pathways for pancreatic cancer cachexia using an aptamer-based discovery platform. Cancers 12, https:\/\/doi.org\/10.3390\/cancers12123787 (2020).","DOI":"10.3390\/cancers12123787"},{"key":"35649_CR25","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-0204-03","volume":"10","author":"A Paju","year":"2004","unstructured":"Paju, A. et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin. Cancer Res. 10, 4761\u20134768 (2004).","journal-title":"Clin. Cancer Res."},{"key":"35649_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-10-45","volume":"10","author":"T Rajkumar","year":"2010","unstructured":"Rajkumar, T. et al. Identification and validation of genes involved in gastric tumorigenesis. Cancer Cell Int. 10, 45 (2010).","journal-title":"Cancer Cell Int."},{"key":"35649_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng1797","volume":"38","author":"H Witt","year":"2006","unstructured":"Witt, H. et al. A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat. Genet. 38, 668\u2013673 (2006).","journal-title":"Nat. Genet."},{"key":"35649_CR28","doi-asserted-by":"publisher","first-page":"39484","DOI":"10.1074\/jbc.M104382200","volume":"276","author":"I Mikhailenko","year":"2001","unstructured":"Mikhailenko, I. et al. Recognition of alpha 2-macroglobulin by the low density lipoprotein receptor-related protein requires the cooperation of two ligand binding cluster regions. J. Biol. Chem. 276, 39484\u201339491 (2001).","journal-title":"J. Biol. Chem."},{"key":"35649_CR29","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4049\/jimmunol.181.1.364","volume":"181","author":"AP Lillis","year":"2008","unstructured":"Lillis, A. P. et al. Murine low-density lipoprotein receptor-related protein 1 (LRP) is required for phagocytosis of targets bearing LRP ligands but is not required for C1q-triggered enhancement of phagocytosis. J. Immunol. 181, 364\u2013373 (2008).","journal-title":"J. Immunol."},{"key":"35649_CR30","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1111\/j.1538-7836.2005.01371.x","volume":"3","author":"AP Lillis","year":"2005","unstructured":"Lillis, A. P., Mikhailenko, I. & Strickland, D. K. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J. Thromb. Haemost. 3, 1884\u20131893 (2005).","journal-title":"J. Thromb. Haemost."},{"key":"35649_CR31","doi-asserted-by":"publisher","first-page":"14259","DOI":"10.1074\/jbc.M109.085126","volume":"285","author":"E Mantuano","year":"2010","unstructured":"Mantuano, E., Jo, M., Gonias, S. L. & Campana, W. M. Low density lipoprotein receptor-related protein (LRP1) regulates Rac1 and RhoA reciprocally to control Schwann cell adhesion and migration. J. Biol. Chem. 285, 14259\u201314266 (2010).","journal-title":"J. Biol. Chem."},{"key":"35649_CR32","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1074\/jbc.M116.761650","volume":"292","author":"P Merino","year":"2017","unstructured":"Merino, P. et al. Urokinase-type plasminogen activator (uPA) binding to the uPA receptor (uPAR) promotes axonal regeneration in the central nervous system. J. Biol. Chem. 292, 2741\u20132753 (2017).","journal-title":"J. Biol. Chem."},{"key":"35649_CR33","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1083\/jcb.147.5.1009","volume":"147","author":"EE Sander","year":"1999","unstructured":"Sander, E. E., ten Klooster, J. P., van Delft, S., van der Kammen, R. A. & Collard, J. G. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J. Cell Biol. 147, 1009\u20131022 (1999).","journal-title":"J. Cell Biol."},{"key":"35649_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1242\/jcs.03341","volume":"120","author":"MJ Williams","year":"2007","unstructured":"Williams, M. J., Habayeb, M. S. & Hultmark, D. Reciprocal regulation of Rac1 and Rho1 in Drosophila circulating immune surveillance cells. J. Cell Sci. 120, 502\u2013511 (2007).","journal-title":"J. Cell Sci."},{"key":"35649_CR35","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1083\/jcb.149.4.775","volume":"149","author":"GC Zondag","year":"2000","unstructured":"Zondag, G. C. et al. Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J. Cell Biol. 149, 775\u2013782 (2000).","journal-title":"J. Cell Biol."},{"key":"35649_CR36","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1073\/pnas.0307512101","volume":"101","author":"Y Gao","year":"2004","unstructured":"Gao, Y., Dickerson, J. B., Guo, F., Zheng, J. & Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl Acad. Sci. USA 101, 7618\u20137623 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"35649_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1023\/A:1011022822077","volume":"216","author":"SA Kim","year":"2001","unstructured":"Kim, S. A., Um, S. J., Kang, J. H. & Hong, K. J. Expression of thrombospondin-1 in human hepatocarcinoma cell lines and its regulation by transcription factor Jun\/AP-1. Mol. Cell Biochem 216, 21\u201329 (2001).","journal-title":"Mol. Cell Biochem"},{"key":"35649_CR38","doi-asserted-by":"publisher","first-page":"e11584","DOI":"10.1371\/journal.pone.0011584","volume":"5","author":"B Langlois","year":"2010","unstructured":"Langlois, B. et al. LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS ONE 5, e11584 (2010).","journal-title":"PLoS ONE"},{"key":"35649_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0772-7","volume":"13","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. LRP1 modulates the microglial immune response via regulation of JNK and NF-\u03baB signaling pathways. J. Neuroinflammation 13, 304 (2016).","journal-title":"J. Neuroinflammation"},{"key":"35649_CR40","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1471-4159.2005.03252.x","volume":"94","author":"SS Le","year":"2005","unstructured":"Le, S. S. et al. Inhibition of Rac GTPase triggers a c-Jun- and Bim-dependent mitochondrial apoptotic cascade in cerebellar granule neurons. J. Neurochem 94, 1025\u20131039 (2005).","journal-title":"J. Neurochem"},{"key":"35649_CR41","doi-asserted-by":"publisher","first-page":"e0212323","DOI":"10.1371\/journal.pone.0212323","volume":"16","author":"Y Matsuoka","year":"2021","unstructured":"Matsuoka, Y., Al-Shareef, H., Kogo, M. & Nakahara, H. Effects of decreased Rac activity and malignant state on oral squamous cell carcinoma in vitro. PLoS ONE 16, e0212323 (2021).","journal-title":"PLoS ONE"},{"key":"35649_CR42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/djj068","volume":"98","author":"GN Naumov","year":"2006","unstructured":"Naumov, G. N. et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl Cancer Inst. 98, 316\u2013325 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"35649_CR43","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1038\/onc.2014.228","volume":"34","author":"RS Watnick","year":"2015","unstructured":"Watnick, R. S. et al. Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells. Oncogene 34, 2823\u20132835 (2015).","journal-title":"Oncogene"},{"key":"35649_CR44","first-page":"717","volume":"44","author":"TH Corbett","year":"1984","unstructured":"Corbett, T. H. et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL\/6 mice. Cancer Res. 44, 717\u2013726 (1984).","journal-title":"Cancer Res."},{"key":"35649_CR45","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/ajg.2017.218","volume":"112","author":"J Kirkegard","year":"2017","unstructured":"Kirkegard, J., Mortensen, F. V. & Cronin-Fenton, D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am. J. Gastroenterol. 112, 1366\u20131372 (2017).","journal-title":"Am. J. Gastroenterol."},{"key":"35649_CR46","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/s41395-018-0255-9","volume":"113","author":"O Sadr-Azodi","year":"2018","unstructured":"Sadr-Azodi, O. et al. Pancreatic cancer following acute pancreatitis: a population-based matched cohort study. Am. J. Gastroenterol. 113, 1711\u20131719 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"35649_CR47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat. Immunol. 21, 298\u2013308 (2020).","journal-title":"Nat. Immunol."},{"key":"35649_CR48","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1083\/jcb.138.3.707","volume":"138","author":"DW Dawson","year":"1997","unstructured":"Dawson, D. W. et al. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707\u2013717 (1997).","journal-title":"J. Cell Biol."},{"key":"35649_CR49","doi-asserted-by":"publisher","first-page":"15404","DOI":"10.1074\/jbc.M701638200","volume":"282","author":"JS Isenberg","year":"2007","unstructured":"Isenberg, J. S. et al. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J. Biol. Chem. 282, 15404\u201315415 (2007).","journal-title":"J. Biol. Chem."},{"key":"35649_CR50","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/jcp.20904","volume":"210","author":"J Greenaway","year":"2007","unstructured":"Greenaway, J. et al. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J. Cell Physiol. 210, 807\u2013818 (2007).","journal-title":"J. Cell Physiol."},{"key":"35649_CR51","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/jcb.10781","volume":"91","author":"S Wang","year":"2004","unstructured":"Wang, S. et al. Internalization but not binding of thrombospondin-1 to low density lipoprotein receptor-related protein-1 requires heparan sulfate proteoglycans. J. Cell Biochem. 91, 766\u2013776 (2004).","journal-title":"J. Cell Biochem."},{"key":"35649_CR52","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fimmu.2018.00974","volume":"9","author":"KG Sundqvist","year":"2018","unstructured":"Sundqvist, K. G. T cell co-stimulation: inhibition of immunosuppression? Front. Immunol. 9, 974 (2018).","journal-title":"Front. Immunol."},{"key":"35649_CR53","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4049\/jimmunol.1800878","volume":"202","author":"N Sorrelle","year":"2019","unstructured":"Sorrelle, N. et al. Improved multiplex immunohistochemistry for immune microenvironment evaluation of mouse formalin-fixed, paraffin-embedded tissues. J. Immunol. 202, 292\u2013299 (2019).","journal-title":"J. Immunol."},{"key":"35649_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 1\u20137 (2017).","journal-title":"Sci. Rep."},{"key":"35649_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00862-w","volume":"7","author":"K Kruger","year":"2017","unstructured":"Kruger, K. et al. Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Sci. Rep. 7, 1089 (2017).","journal-title":"Sci. Rep."},{"key":"35649_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59728-3","volume":"10","author":"C Askeland","year":"2020","unstructured":"Askeland, C. et al. Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups. Sci. Rep. 10, 2914 (2020).","journal-title":"Sci. Rep."},{"key":"35649_CR57","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1158\/0008-5472.CAN-05-1163","volume":"66","author":"IM Stefansson","year":"2006","unstructured":"Stefansson, I. M., Salvesen, H. B. & Akslen, L. A. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res. 66, 3303\u20133309 (2006).","journal-title":"Cancer Res."},{"key":"35649_CR58","first-page":"6808","volume":"62","author":"O Straume","year":"2002","unstructured":"Straume, O. et al. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res. 62, 6808\u20136811 (2002).","journal-title":"Cancer Res."},{"key":"35649_CR59","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5","volume":"74","author":"O Straume","year":"1997","unstructured":"Straume, O. & Akslen, L. A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int. J. Cancer 74, 535\u2013539 (1997).","journal-title":"Int. J. Cancer"},{"key":"35649_CR60","first-page":"4071","volume":"21","author":"OJ Halvorsen","year":"2001","unstructured":"Halvorsen, O. J., Haukaas, S., Hoisaeter, P. A. & Akslen, L. A. Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Res. 21, 4071\u20134076 (2001).","journal-title":"Anticancer Res."},{"key":"35649_CR61","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1158\/0008-5472.CAN-08-4417","volume":"69","author":"K Gravdal","year":"2009","unstructured":"Gravdal, K., Halvorsen, O. J., Haukaas, S. A. & Akslen, L. A. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res. 69, 4708\u20134715 (2009).","journal-title":"Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35649-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35649-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35649-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T03:36:53Z","timestamp":1679197013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-35649-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["35649"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-35649-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S. Watnick is a co-founder of, and consultant for, Vigeo Therapeutics, which has licensed technology from Boston Children\u2019s Hospital. The work in this report was done independently and without financial support from Vigeo. The remaining authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7959"}}